Logo image of MGTX

MEIRAGTX HOLDINGS PLC (MGTX) Stock Fundamental Analysis

USA - NASDAQ:MGTX - KYG596651029 - Common Stock

8.18 USD
-0.01 (-0.12%)
Last: 9/26/2025, 8:12:10 PM
8.18 USD
0 (0%)
After Hours: 9/26/2025, 8:12:10 PM
Fundamental Rating

2

Overall MGTX gets a fundamental rating of 2 out of 10. We evaluated MGTX against 540 industry peers in the Biotechnology industry. MGTX may be in some trouble as it scores bad on both profitability and health. MGTX shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MGTX has reported negative net income.
MGTX had a negative operating cash flow in the past year.
MGTX had negative earnings in each of the past 5 years.
MGTX had a negative operating cash flow in each of the past 5 years.
MGTX Yearly Net Income VS EBIT VS OCF VS FCFMGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

MGTX has a Return On Assets of -79.26%. This is in the lower half of the industry: MGTX underperforms 67.04% of its industry peers.
MGTX has a worse Return On Equity (-5321.11%) than 83.70% of its industry peers.
Industry RankSector Rank
ROA -79.26%
ROE -5321.11%
ROIC N/A
ROA(3y)-40.41%
ROA(5y)-32.41%
ROE(3y)-129.61%
ROE(5y)-91.21%
ROIC(3y)N/A
ROIC(5y)N/A
MGTX Yearly ROA, ROE, ROICMGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

The Gross Margin of MGTX (26.56%) is better than 72.78% of its industry peers.
MGTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 26.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MGTX Yearly Profit, Operating, Gross MarginsMGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

0

2. Health

2.1 Basic Checks

MGTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MGTX has been increased compared to 1 year ago.
MGTX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MGTX is higher compared to a year ago.
MGTX Yearly Shares OutstandingMGTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MGTX Yearly Total Debt VS Total AssetsMGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -5.95, we must say that MGTX is in the distress zone and has some risk of bankruptcy.
MGTX has a worse Altman-Z score (-5.95) than 63.89% of its industry peers.
MGTX has a Debt/Equity ratio of 24.92. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 24.92, MGTX is not doing good in the industry: 84.07% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 24.92
Debt/FCF N/A
Altman-Z -5.95
ROIC/WACCN/A
WACC10.67%
MGTX Yearly LT Debt VS Equity VS FCFMGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

MGTX has a Current Ratio of 0.88. This is a bad value and indicates that MGTX is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.88, MGTX is doing worse than 88.52% of the companies in the same industry.
A Quick Ratio of 0.88 indicates that MGTX may have some problems paying its short term obligations.
MGTX has a worse Quick ratio (0.88) than 88.15% of its industry peers.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.88
MGTX Yearly Current Assets VS Current LiabilitesMGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

8

3. Growth

3.1 Past

MGTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.93%, which is quite good.
The Revenue has grown by 367.02% in the past year. This is a very strong growth!
Measured over the past years, MGTX shows a very strong growth in Revenue. The Revenue has been growing by 20.15% on average per year.
EPS 1Y (TTM)8.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.84%
Revenue 1Y (TTM)367.02%
Revenue growth 3Y-4.07%
Revenue growth 5Y20.15%
Sales Q2Q%1208.87%

3.2 Future

Based on estimates for the next years, MGTX will show a very strong growth in Earnings Per Share. The EPS will grow by 35.37% on average per year.
MGTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 100.14% yearly.
EPS Next Y13.44%
EPS Next 2Y42.9%
EPS Next 3Y15.9%
EPS Next 5Y35.37%
Revenue Next Year496.23%
Revenue Next 2Y300.17%
Revenue Next 3Y125.2%
Revenue Next 5Y100.14%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MGTX Yearly Revenue VS EstimatesMGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
MGTX Yearly EPS VS EstimatesMGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MGTX. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 91.13, which means the current valuation is very expensive for MGTX.
MGTX's Price/Forward Earnings ratio is rather cheap when compared to the industry. MGTX is cheaper than 87.04% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.89. MGTX is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 91.13
MGTX Price Earnings VS Forward Price EarningsMGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGTX Per share dataMGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as MGTX's earnings are expected to grow with 15.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.9%
EPS Next 3Y15.9%

More info and screens

0

5. Dividend

5.1 Amount

MGTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEIRAGTX HOLDINGS PLC

NASDAQ:MGTX (9/26/2025, 8:12:10 PM)

After market: 8.18 0 (0%)

8.18

-0.01 (-0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners49.28%
Inst Owner Change6.62%
Ins Owners4.27%
Ins Owner Change-2.25%
Market Cap658.08M
Analysts83.33
Price Target27.88 (240.83%)
Short Float %7.26%
Short Ratio7.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.7%
Min EPS beat(2)-2.74%
Max EPS beat(2)-0.66%
EPS beat(4)1
Avg EPS beat(4)1.59%
Min EPS beat(4)-2.74%
Max EPS beat(4)12.47%
EPS beat(8)2
Avg EPS beat(8)-42.26%
EPS beat(12)4
Avg EPS beat(12)-31.88%
EPS beat(16)5
Avg EPS beat(16)-24.24%
Revenue beat(2)0
Avg Revenue beat(2)-56.1%
Min Revenue beat(2)-57.41%
Max Revenue beat(2)-54.78%
Revenue beat(4)2
Avg Revenue beat(4)435.97%
Min Revenue beat(4)-57.41%
Max Revenue beat(4)1298.04%
Revenue beat(8)3
Avg Revenue beat(8)192.16%
Revenue beat(12)3
Avg Revenue beat(12)106.14%
Revenue beat(16)7
Avg Revenue beat(16)120.75%
PT rev (1m)0%
PT rev (3m)18.84%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.16%
EPS NY rev (1m)0%
EPS NY rev (3m)-428.51%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)-9.25%
Revenue NY rev (1m)-0.36%
Revenue NY rev (3m)-47.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 91.13
P/S 17.36
P/FCF N/A
P/OCF N/A
P/B 222.32
P/tB 296.7
EV/EBITDA N/A
EPS(TTM)-2.04
EYN/A
EPS(NY)0.09
Fwd EY1.1%
FCF(TTM)-1.67
FCFYN/A
OCF(TTM)-1.6
OCFYN/A
SpS0.47
BVpS0.04
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -79.26%
ROE -5321.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 26.56%
FCFM N/A
ROA(3y)-40.41%
ROA(5y)-32.41%
ROE(3y)-129.61%
ROE(5y)-91.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 24.92
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.82%
Cap/Sales 12.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.88
Quick Ratio 0.88
Altman-Z -5.95
F-Score3
WACC10.67%
ROIC/WACCN/A
Cap/Depr(3y)233.72%
Cap/Depr(5y)368.57%
Cap/Sales(3y)147.08%
Cap/Sales(5y)142.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.84%
EPS Next Y13.44%
EPS Next 2Y42.9%
EPS Next 3Y15.9%
EPS Next 5Y35.37%
Revenue 1Y (TTM)367.02%
Revenue growth 3Y-4.07%
Revenue growth 5Y20.15%
Sales Q2Q%1208.87%
Revenue Next Year496.23%
Revenue Next 2Y300.17%
Revenue Next 3Y125.2%
Revenue Next 5Y100.14%
EBIT growth 1Y6.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year145.74%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.84%
OCF growth 3YN/A
OCF growth 5YN/A